Loading…
← CockpitCompetitor Analysis › 600201.SS Jinyu Bio-Technology Co., Ltd. Class AOpen in the cockpit ↗

Jinyu Bio-Technology Co., Ltd. Class A600201.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Inner Mongolia veterinary biologics maker best known for foot-and-mouth disease vaccines for pigs and cattle.

≈ A livestock-vaccine Zoetis, but China-onlyMomentum strong 62
Mkt cap
$1.93B
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$23.7M
20-day average traded
Fwd P/E
59.0×
forward earnings
ROIC−WACC
-2.5 pp
WACC 8.8%
Hurdle
+26 pp
Req g minus delivered
Next earnings
149 days
16 Apr 2027
Close · CNYCN¥11.81
1D-0.8%
1W-2.5%
1M-6.4%
3M-13.4%
6M-21.3%
YTD-21.6%
1Y+12.9%
ATR %3.5%
52w lowhigh37.8% off high

What Jinyu Bio-Technology does

Inner Mongolia veterinary biologics maker best known for foot-and-mouth disease vaccines for pigs and cattle.

Sells vaccines both to provincial animal-husbandry bureaus that buy for mandatory immunisation programmes and to farms directly, so a government purchase cycle and the size of herds set demand.

In one line: A livestock-vaccine Zoetis, but China-only.

Products and services

  • Foot-and-mouth disease vaccine
  • Other livestock vaccines
  • Veterinary diagnostics

Customers

  • Pig and cattle farms
  • Provincial animal husbandry bureaus

Where it sits in the supply chain

  • Animal health
  • Veterinary biologics
  • Livestock vaccines

What could go right

  • Livestock herd rebuilding after disease outbreaks
  • Government-mandated vaccination programs

What could go wrong

  • Animal disease-cycle demand swings
  • State price controls on mandatory vaccines

Moat: narrow (regulatory licence, scale). One of a small number of licensed FMD-vaccine producers under China's state biosecurity program.

Headquarters: Hohhot, Inner Mongolia, China · Employees: 1,881

Named competitors

Jinyu Bio-Technology at a glance

Size Jinyu Bio-Technology (600201.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.93B, the 1203rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.81 on 18 Nov 2026.

Performance Over six months the shares fell 21.3%, against -1.3% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 21.9% over the last twelve months (peer median +8.7%); the operating margin is 9.7% (peer median 20.9%).

Valuation It trades at 59.0× forward earnings against a peer median of 20.0× (2nd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points below its cost of capital (8.8% WACC).

Next results Next results expected around 16 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026Peer median 97600201.SS 83
Six months, rebased to 100: Jinyu Bio-Technology against the median of its 20 peers (local-currency closes).

Jinyu Bio-Technology financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.60BCN¥1.39BCN¥1.23BCN¥1.59BCN¥1.52B
Revenue growth—+13%-22%+5%—
Gross profitCN¥997MCN¥621MCN¥571MCN¥882MCN¥759M
EBITDAn/aCN¥258MCN¥251MCN¥436MCN¥452M
Net incomeCN¥165MCN¥100MCN¥109MCN¥284MCN¥211M
Free cash flowCN¥259MCN¥222MCN¥255MCN¥166MCN¥190M
Capital expenditureCN¥123MCN¥121MCN¥89.7MCN¥273MCN¥190M
Total debtCN¥334MCN¥75.7MCN¥161MCN¥218MCN¥24.5M

Quarterly statements and history in the cockpit →

Jinyu Bio-Technology competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%45400512HRMYONESOURCEBHVNSHILPAMEDALIVUSERISPFIZER300009600211COHANCE9969009420000908300436DMP603456603707600285600201.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Jinyu Bio-Technology is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×45400512ONESOURCESHILPAMEDALIVUSERISPFIZER300009COHANCE9969DMP603707600201.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jinyu Bio-Technology is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%0512HRMYALIVUSPFIZER9969600201.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jinyu Bio-Technology is the large dot.

Jinyu Bio-Technology competitors and peer comparison

Head to head with its named competitors (600201.SS vs 603566.SS vs ZTS vs 300119.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jinyu Bio-Technology 600201.SS$1.93B-21%+22%10%59.0×23.4%
Pulike Biological Engineering 603566.SS$449M-21%-9%5%23.2×4.5%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Tianjin Ringpu Bio-technology 300119.SZ$1.11B-7%-9%11%18.1×4.9%
China Animal Husbandry Industry 600195.SS$921M-16%+1%2%41.5×6.1%

How Jinyu Bio-Technology compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jinyu Bio-Technology against its 20 peers (data as of 18 Nov 2026)
Measure600201.SSPeer medianRank in peer set
1-month return-6.4%+2.7%8th lowest of 21
6-month return-21.3%-1.3%5th lowest of 21
Distance from 52-week high-37.8%-28.2%4th lowest of 21
Revenue growth (TTM)+21.9%+8.7%3rd highest of 20
Operating margin9.7%20.9%6th lowest of 20
Forward P/E59.0×20.0×2nd most expensive of 17
Growth the price implies (Req g, 7 yrs)23.4%1.5%2nd most demanding of 13
Growth delivered (Del g)-2.5%+12.3%lowest of 13
Hurdle (Req g minus delivered)+25.9 pp-12.1 ppmost demanding of 13
ROIC minus cost of capital-2.5 pp+1.6 pp6th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%

Questions

Who are Jinyu Bio-Technology's main competitors?
Named competitors: Pulike Biological Engineering (603566.SS), Zoetis (ZTS), Ringpu Bio-technology (300119.SZ), China Animal Husbandry Industry (600195.SS). The cockpit's measured peer set (industry) also includes Tsumura & (4540.T), Grand Pharmaceutical (0512.HK), Harmony Biosciences (HRMY), OneSource Specialty Pharma (ONESOURCE.NS), Biohaven (BHVN), Shilpa Medicare (SHILPAMED.NS).
Is Jinyu Bio-Technology expensive compared with its peers?
On forward p/e it trades at 59.0× against a peer median of 20.0×, 2nd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 23% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jinyu Bio-Technology stock performed?
Over six months to 18 Nov 2026 the shares returned -21.3% against -1.3% for the median peer; over one year +12.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.